SAN DIEGO and BASEL, Switzerland , April 17, 2025 (Korea Bizwire) — Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. “It is a pleasure to welcome John to our Board,” said [...]
BASEL, Switzerland and SAN DIEGO, Jan. 6 (Korea Bizwire) — Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced that Fredrik Wiklund, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14th, 2025, at 2:30 p.m. Pacific Time. The Company [...]
– BPT958, a bifunctional PD-1 immunoconjugate with a masked IL-2 payload designed to be processed specifically in the tumor microenvironment - –In preclinical models, BPT958 induces potent antitumor activity with minimal systemic activation - BASEL, Switzerland and SAN DIEGO, Nov. 08, 2024 (Korea Bizwire) – Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering [...]
– BPT567 is the first bifunctional PD1-IL18 immunoconjugate to enter clinical development – – Phase 1/2a study will evaluate BPT567 in patients with locally advanced/unresectable or metastatic solid tumors – BASEL, Switzerland and SAN DIEGO, Oct. 17, 2024 (Korea Bizwire) – Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies [...]
– Lead Program, BPT567, will be the first PD1-IL18 immunoconjugate to enter the clinic; Phase 1/2a study in solid tumors expected to begin in 2H 2024 – – Financing led by Johnson & Johnson with participation by new and existing investors – BASEL, Switzerland and SAN DIEGO, June 11, 2024 (Korea Bizwire) – Bright Peak Therapeutics, [...]
BPT567, a first-in-class PD1-IL18 immunoconjugate designed to enable cis-signaling and preferentially activate intratumoral PD1+IL18R+ effector T cells induces potent preclinical antitumor activity SAN DIEGO and BASEL, Switzerland, Apr. 9 (Korea Bizwire) — Bright Peak Therapeutics, a biotechnology company developing multifunctional immunotherapies for cancer and autoimmune disease, today announced the presentation of new data characterizing the [...]
SAN DIEGO and BASEL, Switzerland, Oct. 20 (Korea Bizwire) — Bright Peak Therapeutics, a privately held biotechnology company developing next-generation multifunctional precision immunotherapies, today announced the presentation of two posters showcasing the potential of its unique chemical protein engineering platform at the 10th International Conference on Autoimmunity: Mechanisms and Novel Treatments taking place October 20-25, 2022, [...]
SAN DIEGO & BASEL, Switzerland, Oct. 18 (Korea Bizwire) — Bright Peak Therapeutics, a privately held biotechnology company leveraging a revolutionary chemical protein engineering platform to develop next-generation multifunctional cytokine-based immunotherapies, today announced the formation of a Scientific Advisory Board (“SAB”) comprised of world-renowned experts in immuno-oncology basic, translational and clinical research. “Bright Peak is [...]
SAN DIEGO and BASEL, Switzerland, Aug. 22 (Korea Bizwire) — Bright Peak Therapeutics, a biotechnology company developing next-generation precision immunotherapies to treat cancer and autoimmune disease, today announced the appointment of Jon Wigginton, M.D., as its President of Research and Development. “With a lifelong dedication to improving the lives of patients with cancer, Dr. Wigginton [...]
SAN DIEGO and BASEL, Switzerland, April 4 (Korea Bizwire) — Bright Peak Therapeutics, a biotechnology company developing next-generation cytokine immunotherapies to treat cancer and autoimmune disease, today announced the acceptance of one oral presentation and two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting taking place April 8-13, 2022, in New [...]